GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

Date: 18/07/2019

To,
The Manager,
Listing Department,
BSE Limited,
Bombay Stock Exchange,
P.J. Towers, Dalal Street,
Mumbai – 400 001

Subject: Statement of Investor Complaints for the quarter ended 30th June, 2019. **Ref:** Scrip code 956084 and ISIN INE988W07019

Dear Sir/Madam,

With reference to the subject matter, please find enclosed herewith the disclosure as required under Regulation 13 (3) of Chapter III of SEBI (Listing Obligations and Disclosure Requirements), 2015 for the quarter ended 30th June, 2019.

We kindly request you to take the said information on your records.

Thanking you.

For Genlink Pharma Solutions Private Limited

Ganeshprasad Gupta

Company Secretary CompHance Officer

Membership No. ACS33925

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

Disclosure under Regulation 13(3) of Chapter III of SEBI (Listing Obligations and Disclosure Requirements), 2015 for the quarter ended 30th June, 2019

Particulars	Status of complaints
Investor complaints pending at the beginning of the quarter	Nil
Investor complaints received during the quarter	Nil
Investor complaints disposed of during the quarter	Not applicable
Investor complaints remaining unresolved at the end of the quarter	Nil

For Genlink Pharma Solutions Private Limited

Ganeshprasad Gupta

Company Secretary & Compliance Officer

Membership No. ACS33925 Ad